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Mortality associated with
pneumonectomy after induction
chemoradiation versus
chemotherapy alone in stage
IIIA-N2 non–small cell lung
cancer
To the Editor:
I read with great interest the recent article
of the Toronto group on improved results
of induction chemoradiation followed by sur-
gery for selected patients with stage IIIA-N2
non–small cell lung cancer.1 Uy and col-
leagues1 are to be congratulated for their
detailed analysis and honest data reporting
regarding this difficult subset of patients
with N2 disease for whom the optimal treat-
ment remains to be defined. As in the Inter-
group-0139 trial,2 Uy and colleagues1
adopted an induction therapy of concurrent
chemotherapy and radiotherapy, followed
by surgical resection if there was no progres-
sive disease on restaging. In 11 cases
(27.5%), pneumonectomy was necessary.
As previously observed in the INT-0139 trial,
mortality in this setting was high: 27% over-
all, and even 50% for complex pneumonecto-
mies. Causes of death were adult respiratory
distress syndrome and postoperative hemor-
rhage. After induction therapy followed by
pneumonectomy, higher incidences have
been reported for empyema, bronchopleural
fistula, and adult respiratory distress syn-
drome than are seen after standard resection
without induction therapy.3
Uy and colleagues1 referred to European
Organization for Research and Treatment of
Cancer trial 08941, results of which were
recently reported.3,4 In this multicenter trial,
patients with histologically proven stage
IIIA-N2 non–small cell lung cancer were
treated with induction chemotherapy—
without radiotherapy—and in case of
response were subsequently randomly as-
signed to undergo either surgery or radio-
therapy. Pneumonectomy was performed in
46.8% of patients; the 30-day mortality in
this subgroup was 6.9%, which was much
lower than those reported by Uy and col-
leagues1 and in the INT-0139 trial.2 Similar
results as in the EORTC 08941 study were
recently published by a group from Stras-
bourg; they reported a 30-day mortality of
6.7% in a series of 60 patients under-
going pneumonectomy after induction
chemotherapy.5
Although Uy and colleagues1 did not
specifically comment on this issue, the
type of induction therapy—chemotherapy
versus combined chemoradiotherapy—
may be important in explaining this mortal-
ity difference. Unfortunately, there are no
randomized studies directly comparing in-
duction chemotherapy with chemoradio-
therapy with respect to outcome after
surgical resection for locally advanced
non–small cell lung cancer.
Although a pneumonectomy can be
safely performed after induction chemother-
apy, it remains a high-risk procedure after
induction chemoradiotherapy, especially
when a complex procedure has to be per-
formed on the right side. Coverage of the
bronchial stump with viable tissue is essen-
tial to prevent the dreadful complication of
bronchial stump dehiscence.
Paul E. Van Schil, MD, PhD
Department of Thoracic and Vascular Surgery
University Hospital of Antwerp
Antwerp, Belgium
Dr Van Schil reports lecture fees from Pierre Fa-
bre Oncology (Laboratoires Pierre Fabre, Castres,
France).
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Dr Van Schil’s letter clearly enunciates the
concern of many surgeons that the combina-
tion of chemotherapy and radiation for in-
duction increases the risk of subsequent
surgical intervention, whereas the use of
induction chemotherapy alone does not.
Although the report from Martin and
colleagues,1 as well as the data from the In-
tergroup 0139 trial,2 support this concern,
we believe this not to be the case. In our ex-
perience, as outlined in our report, the mor-
talities all occurred early in our experience
with this protocol. There were no mortalities
in the last 34 patients, including those
undergoing pneumonectomy. In doing the
chart audit, we noted that the mortalities in
the patients undergoing pneumonectomy
occurred in patients with large, bulky central
tumors, in whom the hilar dissection could
be anticipated to be difficult. In retrospect,
we would now not consider such patients
for resection. Based on our own experience,
we do not think that induction chemoradia-
tion results in excessive risk for resection
if patients are selected appropriately. Fur-
thermore, this is supported by the work of
Sonett and colleagues,3 who used even
higher doses of radiation without any oper-
ative mortality.
In selecting patients for trimodality ther-
apy, we believe that both the primary and
Letters to the Editornodal disease must be technically resectable
before induction. In particular, the nodes
should not be fixed to the airway, nor should
the proximal hilar vessels be obliterated by
the nodal disease. The latter is determined
based on the computed tomographic appear-
ance, and the former is assessed at the time
of mediastinoscopy. This speaks to the im-
portance of mediastinoscopy in assessing
the mediastinum, not just for the purpose
of biopsy of the lymph nodes, which could
be done by using endobronchial ultrasound,
but also to assess resectability of the nodes.
Patients must be appropriately selected
for surgical intervention based on their car-
diopulmonary reserve, and it is worthwhile
to repeat functional testing after induction
to ensure that the induction regimen has
not compromised the patient’s cardiac or
pulmonary function.
The timing of resection is important be-
cause beyond 6 to 8 weeks after completionof radiation, fibrosis becomes progressively
more severe and increases the difficulty of
the dissection.
In our experience the combination of
chemotherapy and radiation leads to higher
response rates, with significant downstaging
beyond what one expects with induction
chemotherapy alone. Furthermore, the R0
resection rate using combined therapy is
also increased.
In our center induction chemoradiation
remains the preferred induction regimen
for select patients with N2 disease. We do
not think that induction chemoradiotherapy
prohibitively increases the risk of pneumo-
nectomy, and in fact, it provides an opportu-
nity for curative resection in selected
patients with N2 disease.
Gail Darling, MD, FRCSC
Toronto General Hospital
Division of the University Health NetworkThe Journal of Thoracic and CardiovasculaUniversity of Toronto
Toronto, Ontario, Canada
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